Icure Pharmaceutical Incorporation (175250.KQ) Stock

175250.KQ logo

Icure Pharmaceutical Incorporation

175250.KQSouth Korea
Healthcare

Company profile

Icure Pharmaceutical Incorporation reported revenue of 83.38 billion KRW for fiscal year 2025, up 20.5% from fiscal year 2024. Its largest business segment, Pharmaceutical Business Division, brought in 62% of segment revenue in fiscal year 2024; South Korea was the largest region with 97%. Our analysis of its filings shows revenue growing from 56.81 billion KRW in fiscal year 2023 to 83.38 billion KRW in fiscal year 2025, 21.2% a year on average. Icure Pharmaceutical Incorporation reports about 240 full-time employees.

What stands out

  • It reported a net loss of 33.60 billion KRW in fiscal year 2025, after a profit of 1.05 billion KRW in fiscal year 2024.
  • Its net profit margin over the last four reported quarters was -18.9%, against a median of 1.8% for 6 listed companies of similar size in its industry.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Icure Pharmaceutical Incorporation

Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides body and haircare products, including naturally derived hair and baby line, cleansing tissue, and wet wipes. Further, it offers perfumes, textile perfumes, body mists, and hair and body fragrances. Icure Pharmaceutical Incorporation was founded in 2000 and is based in Seoul, South Korea.

Largest shareholders

  • SoluM Cosmetic Co., Ltd.30.55%
  • Choi Young8.272 %8.27%
  • Sinsin Pharmaceutical Co., Ltd4.70%
  • Deep Dive K-Beauty 2026 Private Equity LP3.92%
  • Yong-soo Hyun0.7321 %0.73%

Share of the company, as of September 25, 2026

Leadership

  • Young-Kwon Choi — CEO, Chairman, CTO, Head of Research & Development, 65

How much revenue does Icure Pharmaceutical Incorporation make?

Icure Pharmaceutical Incorporation reported 83.38 billion KRW in revenue for fiscal year 2025, up 20.5% from 69.21 billion KRW in fiscal year 2024.

What is Icure Pharmaceutical Incorporation's largest business segment?

Pharmaceutical Business Division, with 42.77 billion KRW or 62% of segment revenue in fiscal year 2024. Next: Cosmetics Division (38%).

Where does Icure Pharmaceutical Incorporation make most of its revenue?

South Korea: 97% of revenue by region in fiscal year 2024, followed by Export (3%).

What companies are similar to Icure Pharmaceutical Incorporation?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PharmGen Science, Inc. (004720.KS), Ctcbio Inc. (060590.KQ), Ildong Holdings Co., Ltd. (000230.KS), Jin Yang Pharmaceutical Co., Ltd. (007370.KQ).

Has Icure Pharmaceutical Incorporation made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 38.17 billion KRW; FY2022, a loss of 41.77 billion KRW; FY2023, a loss of 31.42 billion KRW; FY2024, 1.05 billion KRW; FY2025, a loss of 33.60 billion KRW. It reported a net loss in 4 of these 5 years.

How does Icure Pharmaceutical Incorporation's profit margin compare with similar companies?

Net profit margin over the last four reported quarters: Icure Pharmaceutical Incorporation, -18.9%; PharmGen Science, Inc. (004720.KS), 0.1%; Ctcbio Inc. (060590.KQ), 5.7%; Ildong Holdings Co., Ltd. (000230.KS), 3.6%; Jin Yang Pharmaceutical Co., Ltd. (007370.KQ), 18.3%; Myungmoon Pharm co.,Ltd (017180.KS), -0.8%; Bcworld Pharm. Co., Ltd. (200780.KQ), -3.6%.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees240
HeadquartersSeoul, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
SamSung , Icure Tower, Seoul, 06170
Phone
82 2 6959 6909
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Icure Pharmaceutical Incorporation (175250.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/175250.KQ

LinkedInLinkedInXXYouTubeYouTube